For the quarter ending 2025-09-30, CABA had -$85,406K decrease in cash & cash equivalents over the period. -$34,587K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -44,866 | -81,071 |
| Stock-based compensation | 5,815 | 10,866 |
| Depreciation | 345 | 953 |
| Non-cash finance lease expense | 3,479 | 4,884 |
| Non-cash operating lease expense | 931 | 1,787 |
| Accretion of operating lease liabilities | 117 | 309 |
| Amortization of discount on investments | 630 | 35 |
| Loss on foreign currency exchange rates | 85 | 61 |
| Prepaid expenses and other current assets | 905 | 1,012 |
| Other assets | 1,105 | 209 |
| Accounts payable | 1,070 | 2,186 |
| Accrued and other current liabilities | 2,312 | 2,067 |
| Lease liabilities | -1,056 | -2,114 |
| Accrued interest payable under finance lease | -101 | 100 |
| Net cash used in operating activities | -34,509 | -61,228 |
| Purchases of property and equipment | 78 | 946 |
| Purchases of investments | 50,002 | 49,035 |
| Proceeds from maturities of investments | 0 | 0 |
| Net cash (used in) provided by investing activities | -50,080 | -49,981 |
| Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs | -25 | 93,583 |
| Issuance of common stock from atm offering, net of sales agent commission and fees | 0 | 2,595 |
| Proceeds from issuance of common stock in connection with the exercise of stock options | 14 | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 197 |
| Principal payments on finance leases | 795 | 3,554 |
| Net cash provided by financing activities | -806 | 92,821 |
| Effect of exchange rate changes on cash and cash equivalents | -11 | 38 |
| Net decrease in cash and cash equivalents | -85,406 | -18,350 |
| Cash and cash equivalents at beginning of period | 163,962 | - |
| Cash and cash equivalents at end of period | 60,206 | - |
Cabaletta Bio, Inc. (CABA)
Cabaletta Bio, Inc. (CABA)